Executive SummarySyntex has signed a letter of intent to acquire 4.7 mil. shares of Genetic Systems at $8.50 per share, or approximately $40 mil. The agreement would increase Syntex' equity stake in the biotech firm from just under 2% to approximately 18%. In addition, Syntex would also provide approximately $20 mil. over the next five years to fund joint diagnostic R&D focusing primarily on the areas of infectious diseases and cell and tissue typing. The agreement is expected to be completed at the end of July.
You may also be interested in...
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”
CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.
Anticipating a July approval of its cantharidin formulation, Verrica says it is poised to implement a buy-and-bill model for a clinician-administered product with an addressable market of 6 million.